STOCK TITAN

DarioHealth to Report First Quarter 2026 Results on Wednesday, May 13, 2026

(Neutral)
(Neutral)
Tags
earnings date

DarioHealth (Nasdaq: DRIO) will report first quarter 2026 financial results for the period ended March 31, 2026 and will host a live conference call and webcast on Wednesday, May 13, 2026 at 8:30 a.m. ET, before the market opens.

Executives Erez Raphael, Steven Nelson, and Chen Franco-Yehuda will host. A replay will be available through Wednesday, May 27, 2026.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction – DRIO

+2.05%
1 alert
+2.05% Session close to close
$57.60M Market Cap
0.1x Rel. Volume

In the May 4 session, DRIO gained 2.05%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the timing for DarioHealth’s Q1 2026 results and maintains its pattern of pre...
Analysis

This announcement sets the timing for DarioHealth’s Q1 2026 results and maintains its pattern of pre-announcing earnings dates with 8:30 a.m. ET calls led by the same executives. In the background, the company has added financing flexibility via a $100,000,000 shelf registration and a $20,000,000 at-the-market program. Investors may watch how forthcoming results interact with this capital structure and prior earnings trends when assessing future developments.

Key Figures

Shelf registration size: $100,000,000 ATM program size: $20,000,000 ATM commission rate: 3.0% +5 more
8 metrics
Shelf registration size $100,000,000 Form S-3 filed March 19, 2026
ATM program size $20,000,000 424B5 at-the-market offering with A.G.P.
ATM commission rate 3.0% Agent’s commission on ATM gross sales
Shares outstanding 7,300,406 Common shares as of March 19, 2026 (S-3)
Nantahala ownership 688,673 shares Schedule 13G/A as of December 31, 2025
Ownership percentage 9.99% Nantahala beneficial stake in common stock
Director Form 3 stake 4,500 shares John R. Palumbo initial beneficial ownership
Current share price $7.30 Pre-announcement market context

Previous Earnings date Reports

2 past events · Latest: Mar 11 (Neutral)
Same Type Pattern 2 events
Date Event Sentiment 24h Move Catalyst
Mar 11 Earnings date notice Neutral -2.7% Scheduled Q4 and full-year 2025 results with earnings call details.
Nov 06 Earnings date notice Neutral -11.1% Set Q3 2025 results date and outlined standard conference call logistics.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Prior 'earnings date' announcements for DRIO were followed by negative next-day moves despite the routine nature of the news.

Recent Company History

Recent history shows DarioHealth repeatedly pre-announcing results dates with similar call logistics. Two prior earnings date releases on Nov 06, 2025 and Mar 11, 2026 outlined conference call times and replay windows and were followed by next-day share price declines. Against that backdrop, the new notice for Q1 2026 results continues a pattern of routine scheduling updates ahead of full earnings releases and detailed financial disclosures.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Company to host conference call and webcast at 8:30 a.m. Eastern Time

NEW YORK, May 4, 2026 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that it will release its financial results for the 1st quarter ended March 31st, 2026 and will host a conference call and webcast at 8:30 a.m. Eastern Time, on Wednesday, May 13th, 2026, before the market opens.

Erez Raphael, Chief Executive Officer, Steven Nelson, President and Chief Commercial Officer, and Chen Franco-Yehuda, Chief Financial Officer, will host the call.

Conference Call Details

Date: Wednesday, May13th, 2026, 8:30 a.m. Eastern Time

Dial-in Number: 1-800-717-1738 (domestic) or 1-646-307-1865 (international)

Call me™:  https://emportal.ink/4seOwJK

Participants can use the dial-in numbers above and be answered by an operator OR click the Call me™ link for instant telephone access to the event. This link will be made active 15 minutes prior to the scheduled start time.

Webcast link: https://viavid.webcasts.com/starthere.jsp?ei=1756269&tp_key=7306dc53e7

Participants are asked to dial in approximately 10 minutes prior to the start of the event. A replay of the call will be available approximately three hours after completion of the conference call through Wednesday, May 27th, 2026. To listen to the replay, dial 1-844-512-2921 (domestic) or 1-412-317-6671 (international) and use replay passcode 1111468.

About DarioHealth Corp.

DarioHealth Corp. (Nasdaq: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health. 

Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.

Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the expected date of its earnings release. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contact
Zoe Harrison
VP, Accounting and Corporate Development
irteam@dariohealth.com

DarioHealth Investor Relations Contact
Michael Lipari
SVP Corporate Development
irteam@dariohealth.com
+1-203-785-6310

Cision View original content:https://www.prnewswire.com/news-releases/dariohealth-to-report-first-quarter-2026-results-on-wednesday-may-13-2026-302761277.html

SOURCE DarioHealth Corp.

FAQ

When will DarioHealth (DRIO) report Q1 2026 results and hold the earnings call?

DarioHealth will report Q1 2026 results and hold a call on Wednesday, May 13, 2026 at 8:30 a.m. ET. According to the company, the call is scheduled before market open and will include senior management commentary.

How can investors join the DarioHealth (DRIO) May 13, 2026 earnings call?

Investors can join by dialing domestic 1-800-717-1738 or international 1-646-307-1865, or click the Call me™ link. According to the company, the Call me link activates 15 minutes before the start time for instant access.

Where can I watch the DarioHealth (DRIO) Q1 2026 webcast and find the replay?

The live webcast is available via the provided webcast link, with a replay available through Wednesday, May 27, 2026. According to the company, a replay posts about three hours after the call ends and has a replay passcode.

Who will host the DarioHealth (DRIO) Q1 2026 conference call on May 13?

The call will be hosted by CEO Erez Raphael, President Steven Nelson, and CFO Chen Franco-Yehuda. According to the company, these executives will present results and answer participant questions during the session.

What are the dial-in and replay details for the DarioHealth (DRIO) May 13, 2026 call?

Dial-in numbers are 1-800-717-1738 (domestic) and 1-646-307-1865 (international); replay at 1-844-512-2921 or 1-412-317-6671 with passcode 1111468. According to the company, the replay is accessible until May 27, 2026.